Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication ... Dec 22
The results also show that opaganib inhibits SARS-CoV-2 virus replication and proinflammatory markers in relevant preclinical models ... Dec 17
The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease ... Nov 21
Opaganib demonstrated potent antiviral activity against SARS-CoV-2, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. ... Oct 22
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
